Researchers are seeking pregnant patients for the clinical trial of a drug designed to decrease the risk of fetal anemia in patients with hemolytic disease of the fetus and newborn (HDFN).

Please provide your email address to receive an email when new articles are posted on . Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers ...

Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...

Please provide your email address to receive an email when new articles are posted on . Among pregnant women who received nipocalimab infusions, 54% had live births without an intrauterine transfusion ...

Researchers at UK HealthCare are now enrolling patients in the phase 3 AZALEA trial to evaluate the safety and efficacy of an investigational ...

Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to ...

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine ...

Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...

JAUNDICE is a common presentation of Wilson's disease and may precede the neurologic features by many years. 1, 2 Infective hepatitis is often invoked as an explanation of the initial episode, and ...